Every material Form 8-K Repligen filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Repligen reported third-quarter 2025 revenue of $189 million, up 22% from $155 million a year earlier, and GAAP net income of $15 million versus a $1 million loss in the prior-year quarter. The company raised its full-year 2025 revenue guidance to $729 million to $737 million, and GAAP diluted EPS guidance is $0.82 to $0.85.
Q3 2025 revenue was $189 million, up 22% as reported and 18% organic, with no COVID-related revenue in either period.
GAAP diluted EPS was $0.26 versus a loss of $0.01 a year earlier; adjusted diluted EPS was $0.46 versus $0.43.
Full-year 2025 revenue guidance was increased to $729 million to $737 million, with GAAP diluted EPS guidance of $0.82 to $0.85.
Cash and cash equivalents were $749 million at September 30, 2025, compared with $757 million at December 31, 2024.
Repligen appointed Violetta Hughes as its Chief Accounting Officer effective September 1, 2025, replacing Jason K. Garland in the principal accounting officer role. Garland will remain Chief Financial Officer with more time on strategy, financial planning, and capital markets. The change is an administrative leadership update focused on financial reporting and Sarbanes–Oxley oversight.
Violetta Hughes, age 53, becomes Chief Accounting Officer effective September 1, 2025, succeeding Jason K. Garland as principal accounting officer.
Hughes' compensation includes an annual base salary of $395,000 and a one-time signing bonus of $150,000.
Hughes is eligible for a target annual bonus of up to 50% of base salary and an annual equity award worth $750,000.
Jason K. Garland continues as Chief Financial Officer.
Repligen reported second-quarter 2025 revenue of $182 million, up from $159 million a year earlier, and raised its full-year 2025 total reported revenue guidance to $715 million to $735 million. GAAP earnings per share rose to $0.26 from $0.10, while adjusted earnings per share fell to $0.37 from $0.40, a non-GAAP measure.
Q2 2025 revenue was $182 million, up 15% as reported and 17% organic non-COVID growth.
GAAP diluted EPS was $0.26 versus $0.10; adjusted diluted EPS was $0.37 versus $0.40.
Full-year 2025 total reported revenue guidance is $715 million to $735 million; GAAP net income guidance is $48 million to $51.5 million.
Cash, cash equivalents and short-term investments were $709 million at June 30, 2025, versus $757 million at December 31, 2024.
Repligen reported first-quarter 2025 revenue of $169 million, up 10% from $153 million, with 14% organic non-COVID growth and adjusted operating income up 72% year over year. The company reiterated its 2025 organic revenue growth guidance of 9.5% to 13.5% and updated full-year guidance to include the acquisition of 908 Devices' bioprocessing portfolio, which it says adds $10 million to revenue.
Q1 revenue $169 million vs. $153 million a year earlier, up 10% as reported and 14% organic non-COVID growth
GAAP diluted EPS $0.10 vs. $0.06; adjusted diluted EPS $0.39 vs. $0.30
FY2025 guidance: total reported revenue $695 million to $720 million; adjusted diluted EPS $1.63 to $1.72
Cash and cash equivalents $697 million at March 31, 2025, down from $757 million at December 31, 2024
Repligen reported fourth-quarter 2024 revenue of $168 million, up from $167 million, but swung to a GAAP operating loss of $(37) million from $10 million of operating income a year earlier, largely due to $45 million in restructuring and inventory charges. The company also issued 2025 guidance of $685 million to $710 million in reported revenue and GAAP diluted EPS of $0.90 to $0.99, which shareholders can compare with the weaker 2024 profit.
Q4 2024 revenue was $168 million versus $167 million a year earlier; full-year 2024 revenue was $634 million versus $632 million.
Q4 GAAP diluted EPS was $(0.60) versus $(0.29); adjusted EPS was $0.44 versus $0.48.
Q4 GAAP operating loss of $(37) million included $45 million in non-recurring restructuring and other inventory charges.
2025 guidance: total reported revenue of $685 million to $710 million and GAAP diluted EPS of $0.90 to $0.99.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Repligen filing is on SEC EDGAR ↗. 8-K briefs of other companies →